Stockscreener 앱 받기
2.76
1.78%
-0.05
시장 영업 전:
2.80
0.04
+1.45%
Immunitybio Inc 주식(IBRX)의 최신 뉴스
Biotech Breakouts: 3 Stocks With Massive Upside Potential - MarketBeat
Insider Sell: Is ImmunityBio Inc stock a smart retirement pick2025 Biggest Moves & Real-Time Market Sentiment Reports - خودرو بانک
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals - Stocktwits
ETF Watch: Is ImmunityBio Inc. a speculative investmentQuarterly Trade Report & Technical Confirmation Trade Alerts - خودرو بانک
Gainers Report: Is ImmunityBio Inc. forming a double bottomMarket Sentiment Summary & Technical Pattern Based Signals - خودرو بانک
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - Benzinga
Market Leaders: Will ImmunityBio Inc stock benefit from M AJuly 2025 Closing Moves & Daily Oversold Stock Bounce Ideas - خودرو بانک
ImmunityBio's (IBRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Is ImmunityBio Inc. gaining market shareWeekly Trend Report & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Recap Report: Is CDTG stock technically oversoldQuarterly Growth Report & Safe Entry Zone Identification - خودرو بانک
Tech Rally: Does ImmunityBio Inc have a sustainable dividendTake Profit & Consistent Income Trade Ideas - خودرو بانک
Aug Chart Watch: Is ImmunityBio Inc a cyclical or defensive stockJuly 2025 Weekly Recap & Risk Managed Investment Strategies - خودرو بانک
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
RSI Check: Will ImmunityBio Inc benefit from rate cutsPortfolio Risk Report & Precise Swing Trade Entry Alerts - خودرو بانک
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8 - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Trading 7.3% HigherHere's Why - MarketBeat
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio's (IBRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Why ImmunityBio Inc. stock remains a top recommendationJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking (NASDAQ:IBRX) - Seeking Alpha
Breakthrough Findings from Phase 2 QUILT-3.055 Study in NSCLCImmunityBio, Inc. - Oncodaily
H.C. Wainwright reiterates Buy rating on ImmunityBio stock, citing promising lung cancer data - Investing.com India
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer? - MSN
Sentiment Review: Is ImmunityBio Inc. a cyclical or defensive stock2025 Momentum Check & AI Forecasted Entry/Exit Points - Lancaster City Council
ImmunityBio Stock Rebounds: Bright Outlook Ahead? - StocksToTrade
ImmunityBio’s Stock Surge: Health Revolution or Hype? - timothysykes.com
ImmunityBio’s Surprising Performance: What Lies Ahead? - StocksToTrade
Decliners Report: Is ImmunityBio Inc. gaining market shareMarket Sentiment Summary & Fast Moving Trade Plans - Lancaster City Council
Risk Hedge: Does ImmunityBio Inc. have a sustainable dividendJuly 2025 Volume & Long Hold Capital Preservation Tips - Lancaster City Council
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - BioSpace
ImmunityBio Inc. Shows Early Signs of Technical StrengthQuarterly Performance Summary & Technical Pattern Alert System - beatles.ru
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock technically oversoldM&A Rumor & Weekly Top Performers Watchlists - beatles.ru
ImmunityBio’s Anktiva: A Promising Treatment for Long COVID? - TipRanks
Real time scanner hits for ImmunityBio Inc. explainedWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
What momentum shifts mean for ImmunityBio Inc.Analyst Downgrade & Consistent Profit Trade Alerts - Newser
A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study - Yahoo Finance
Rafferty Asset Management LLC Lowers Stock Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Is ImmunityBio Inc. a speculative investment2025 Key Highlights & Free Fast Gain Swing Trade Alerts - 강소기업뉴스
Is ImmunityBio Inc. reversing from oversold territoryJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
ImmunityBio Inc. stock volume spike explainedJuly 2025 Action & Momentum Based Trading Ideas - Newser
How to build a custom watchlist for ImmunityBio Inc.Gap Down & Weekly High Return Forecasts - Newser
What’s next for ImmunityBio Inc. stock price2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Advanced analytics toolkit walkthrough for ImmunityBio Inc.Weekly Investment Recap & Weekly Breakout Stock Alerts - Newser
Applying chart zones and confluence areas to ImmunityBio Inc.Quarterly Portfolio Report & Expert Curated Trade Setups - Newser
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Inc. stock prediction for this week2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Using R and stats models for ImmunityBio Inc. forecasting2025 Price Action Summary & Low Risk Entry Point Tips - Newser
Will ImmunityBio Inc. bounce back from current supportJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - The Globe and Mail
Osteoarthritis Pipeline Analysis, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmu - Barchart.com
What Went Wrong With ImmunityBio’s Executives Claims — and How Investors Could Still Win - TradingView
0.62%
0.57%
자본화:
|
볼륨(24시간):